Jul. 3 at 11:01 AM
$VIR
Thanks for the tip Dr_MoMo:
Also, the following comes with assistance from Grok
Market/China Reaction
The announcement is very fresh (issued from Durham, NC, and Beijing), so it’s generating buzz in biotech and investor circles in China/HK. Brii Bio’s stock (listed in Hong Kong) has historically reacted strongly to positive HBV data.
Recent trading showed volatility, consistent with “exploding” interest on positive news.
China-specific relevance is high: Trials like ENRICH included Chinese sites, NMPA interactions are active, and Breakthrough Therapy Designation was previously granted for elebsiran. This positions Brii well for potential accelerated pathways in Greater China. 
This builds on Brii’s broader HBV pipeline momentum (including prior ENSURE/APASL/EASL data showing immune priming and higher functional cure potential). Full datasets and next steps (e.g., pivotal trial design) will be key watchpoints. (cont)
